Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DARENYSEARCA:DBVOTCMKTS:HIPHNASDAQ:IPA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDAREDaré Bioscience$3.26+5.2%$2.92$2.67▼$6.24$28.85M1.236,589 shs83,081 shsDBVInvesco DB G10 Currency Harvest Fund$25.41$25.41$24.25▼$28.40$25.41M0.2327,852 shsN/AHIPHAmerican Premium Mining$0.00+∞$0.00$0.00▼$0.00$6.44M2.391.99 million shs1.02 million shsIPAImmunoPrecise Antibodies$0.70+22.0%$0.47$0.27▼$1.08$32.04M0.122.15 million shs4.87 million shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDAREDaré Bioscience+5.16%+13.19%+12.41%+10.51%-36.82%DBVInvesco DB G10 Currency Harvest Fund0.00%0.00%0.00%0.00%0.00%HIPHAmerican Premium Mining0.00%0.00%+∞0.00%-75.00%IPAImmunoPrecise Antibodies+22.04%+21.91%+48.94%+78.66%-32.04%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDAREDaré Bioscience1.8461 of 5 stars3.33.00.00.03.60.00.0DBVInvesco DB G10 Currency Harvest FundN/AN/AN/AN/AN/AN/AN/AN/AHIPHAmerican Premium MiningN/AN/AN/AN/AN/AN/AN/AN/AIPAImmunoPrecise Antibodies2.3109 of 5 stars3.55.00.00.00.00.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDAREDaré Bioscience 2.50Moderate Buy$12.00268.10% UpsideDBVInvesco DB G10 Currency Harvest Fund 0.00N/AN/AN/AHIPHAmerican Premium Mining 0.00N/AN/AN/AIPAImmunoPrecise Antibodies 3.00Buy$4.00471.43% UpsideCurrent Analyst Ratings BreakdownLatest HIPH, IPA, DBV, and DARE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2025IPAImmunoPrecise AntibodiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/1/2025DAREDaré BioscienceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.004/1/2025IPAImmunoPrecise AntibodiesBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSpeculative Buy ➝ Speculative Buy$3.00 ➝ $3.003/31/2025IPAImmunoPrecise AntibodiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $5.003/14/2025IPAImmunoPrecise AntibodiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDAREDaré Bioscience$25.91K1,113.55N/AN/A($0.61) per share-5.34DBVInvesco DB G10 Currency Harvest FundN/AN/AN/AN/AN/AN/AHIPHAmerican Premium Mining$70K91.99N/AN/AN/A∞IPAImmunoPrecise Antibodies$24.00M1.33N/AN/A$0.93 per share0.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDAREDaré Bioscience-$30.16M-$0.17N/AN/AN/A-191.65%N/A-18.98%8/11/2025 (Estimated)DBVInvesco DB G10 Currency Harvest FundN/AN/A0.00∞N/AN/AN/AN/AN/AHIPHAmerican Premium MiningN/AN/A0.00∞N/AN/AN/AN/AN/AIPAImmunoPrecise Antibodies-$20.13M-$1.16N/AN/AN/A-114.50%-73.74%-42.68%7/3/2025 (Estimated)Latest HIPH, IPA, DBV, and DARE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025DAREDaré Bioscience-$0.63-$0.50+$0.13-$0.50$0.60 million$0.03 million3/31/2025Q4 2024DAREDaré Bioscience-$0.66-$0.64+$0.02-$0.64$1.00 million($0.06) million3/28/2025Q3 2025IPAImmunoPrecise Antibodies-$0.06-$0.06N/A-$0.46$6.59 million$4.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDAREDaré BioscienceN/AN/AN/AN/AN/ADBVInvesco DB G10 Currency Harvest FundN/AN/AN/AN/AN/AHIPHAmerican Premium MiningN/AN/AN/AN/AN/AIPAImmunoPrecise AntibodiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDAREDaré BioscienceN/A1.141.14DBVInvesco DB G10 Currency Harvest FundN/AN/AN/AHIPHAmerican Premium MiningN/AN/AN/AIPAImmunoPrecise Antibodies0.361.010.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDAREDaré Bioscience6.70%DBVInvesco DB G10 Currency Harvest Fund85.24%HIPHAmerican Premium MiningN/AIPAImmunoPrecise Antibodies6.70%Insider OwnershipCompanyInsider OwnershipDAREDaré Bioscience4.00%DBVInvesco DB G10 Currency Harvest FundN/AHIPHAmerican Premium MiningN/AIPAImmunoPrecise Antibodies6.83%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDAREDaré Bioscience308.85 million8.35 millionNot OptionableDBVInvesco DB G10 Currency Harvest Fund801.00 millionN/ANot OptionableHIPHAmerican Premium Mining164.40 billionN/ANot OptionableIPAImmunoPrecise Antibodies8045.77 million28.94 millionNot OptionableHIPH, IPA, DBV, and DARE HeadlinesRecent News About These CompaniesImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine DiscoveryJune 5 at 8:01 AM | businesswire.comImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement EffortsMay 21, 2025 | businesswire.comImmunoPrecise Antibodies (IPA) to Present at Maxim Group’s 2025 Virtual Tech ConferenceMay 20, 2025 | uk.finance.yahoo.comImmunoPrecise Antibodies to Present at Maxim Group’s 2025 Virtual Tech ConferenceMay 20, 2025 | tipranks.comImmunoPrecise Antibodies (IPA) to Present at Maxim Group's 2025 Virtual Tech ConferenceMay 20, 2025 | businesswire.comIPA’s LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater SpeedMay 12, 2025 | finance.yahoo.comIPA's LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater SpeedMay 12, 2025 | businesswire.comCarterra Announces its 2025 Symposia Series on Speeding Drug Discovery with AI/ML and Other New TechnologiesApril 24, 2025 | finance.yahoo.comImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing MethodsApril 11, 2025 | uk.finance.yahoo.comImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA’s Shift to Non-Animal Testing MethodsApril 11, 2025 | financialpost.comImmunoPrecise Antibodies Partners with RIBOPRO to Enhance Antibody DiscoveryApril 10, 2025 | tipranks.comImmunoPrecise Antibodies (IPA) Upgraded to Buy: What Does It Mean for the Stock?April 3, 2025 | zacks.comImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q3 2025 Earnings Call TranscriptApril 1, 2025 | msn.comImmunoPrecise Antibodies reports Q3 EPS (C$0.66) vs. (C$0.10) last yearMarch 29, 2025 | markets.businessinsider.comIMMUNOPRECISE ANTIBODIES Earnings Preview: Recent $IPA Insider Trading, Hedge Fund Activity, and MoreMarch 28, 2025 | nasdaq.comImmunoPrecise Antibodies Ltd. (IPA) Q3 2025 Earnings Call TranscriptMarch 28, 2025 | seekingalpha.comImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Misses Revenue EstimatesMarch 28, 2025 | zacks.comImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025March 28, 2025 | businesswire.comImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics.March 13, 2025 | financialpost.comImmunoPrecise Antibodies Reschedules Q3 Financial Results ReleaseMarch 11, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings3 Mid-Cap Stocks Turning Heads in AI, Automation, & CybersecurityBy Nathan Reiff | May 16, 2025View 3 Mid-Cap Stocks Turning Heads in AI, Automation, & CybersecurityBroadcom Earnings Preview: AVGO Stock Near Record HighsBy Leo Miller | June 3, 2025View Broadcom Earnings Preview: AVGO Stock Near Record HighsInstitutions Skipped the Rally: Where the Money WentBy Gabriel Osorio-Mazilli | May 8, 2025View Institutions Skipped the Rally: Where the Money WentHIPH, IPA, DBV, and DARE Company DescriptionsDaré Bioscience NASDAQ:DARE$3.26 +0.16 (+5.16%) Closing price 06/5/2025 04:00 PM EasternExtended Trading$3.26 +0.01 (+0.15%) As of 06/5/2025 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.Invesco DB G10 Currency Harvest Fund NYSEARCA:DBV$25.41 0.00 (0.00%) As of 03/10/2023PowerShares DB G10 Currency Harvest Fund (the Fund) is an index tracking fund and does not utilize any trading system, whether discretionary, systematic or otherwise. The Fund offers common units of beneficial interest (the Shares) only to certain eligible financial institutions (the Authorized Participants) in one or more blocks of 200,000 Shares, called a Basket. The Index is designed to reflect the return from investing on a 2:1 leveraged basis in long currency futures positions for certain currencies associated with relatively high yielding interest rates and in short currency futures positions for certain currencies associated with relatively low yielding interest rates. DB Commodity Services LLC serves as the managing owner, commodity pool operator and commodity trading advisor of the Fund.American Premium Mining OTCMKTS:HIPH$0.0001 +0.00 (+∞) As of 06/5/2025 03:20 PM EasternAmerican Premium Mining Corporation focuses on supporting the blockchain ecosystem through proof-of-work and proof-of-stake mining of cryptocurrencies. The company was formerly known as American Premium Water Corporation and changed its name to American Premium Mining Corporation in May 2022. American Premium Mining Corporation is based in Playa Vista, California.ImmunoPrecise Antibodies NASDAQ:IPA$0.70 +0.13 (+22.04%) Closing price 06/5/2025 04:00 PM EasternExtended Trading$0.66 -0.03 (-5.00%) As of 06/5/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
